The grant covering rifaximin, which is on a worldwide basis, excludes the countries of Asia (other than Japan) and Africa, added Salix.
Under an amendment to the prior 2009 agreement, the patent rights covering amorphous rifaximin already licensed to Salix in the US, Canada and Mexico are now expanded to include certain patent rights in the EU, Japan, Australia, New Zealand and South Korea.
This agreement allows Salix to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement for the "Rifaximin Complexes" patent rights. Salix will pay royalties on net sales of products covered by the "Rifaximin Complexes" patents licensed to Salix.
Cipla's XIFAXAN (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia